heptamidine | 94345-47-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: heptamidine
• 英文别名: 4,4'-[heptane-1,7-Diylbis(Oxy)]dibenzenecarboximidamide；4-[7-(4-carbamimidoylphenoxy)heptoxy]benzenecarboximidamide
• CAS: 94345-47-8
• 化学式: C₂₁H₂₈N₄O₂
• 分子量: 368.479
• InChiKey: IUJKKCRARYRWFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  heptamidine 、 异氰酸苯酯 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以68%的产率得到4,4'-(heptane-1,7-diylbis(oxy))bis(N-(phenylcarbamoyl)-benzimidamide)
  参考文献：
  名称：

  Small Molecule Inhibitors of Ca²⁺-S100B Reveal Two Protein Conformations

  摘要：

  The drug pentamidine inhibits calcium-dependent complex formation with p53 ((Ca)S100Bp53) in malignant melanoma (MM) and restores p53 tumor suppressor activity in vivo. However, off-target effects associated with this drug were problematic in MM patients. Structure-activity relationship (SAR) studies were therefore completed here with 23 pentamidine analogues, and X-ray structures of (Ca)S100Binhibitor complexes revealed that the C-terminus of S100B adopts two different conformations, with location of Phe87 and Phe88 being the distinguishing feature and termed the FF-gate. For symmetric pentamidine analogues ((Ca)S100B5a, (Ca)S100B6b) a channel between sites 1 and 2 on S100B was occluded by residue Phe88, but for an asymmetric pentamidine analogue ((Ca)S100B17), this same channel was open. The (Ca)S100B17 structure illustrates, for the first time, a pentamidine analog capable of binding the open form of the FF-gate and provides a means to block all three hot spots on (Ca)S100B, which will impact next generation (Ca)S100Bp53 inhibitor design.

  DOI：

  10.1021/acs.jmedchem.5b01369
• 作为产物：
  描述：

  4-{[7-(4-cyanophenoxy)heptyl]oxy}benzonitrile 在 lithium hexamethyldisilazane 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 以86%的产率得到heptamidine
  参考文献：
  名称：

  使用双脒增强革兰氏阳性特异性抗生素对抗革兰氏阴性病原体的结构-活性研究

  摘要：

  喷他脒是一种 FDA 批准的抗寄生虫药，最近被鉴定为一种外膜破坏增效剂，可增强红霉素、利福平和新生霉素对革兰氏阴性菌的作用。同一项研究还描述了使用市售喷他脒类似物的初步构效关系。我们在这里报告了受喷他脒启发的更广泛的双脒组的设计、合成和评估。本研究既验证了先前观察到的喷他脒的协同活性，同时进一步评估了结构相似的双脒增强革兰氏阳性特异性抗生素对抗革兰氏阴性病原体的能力。在制备的双脒中，发现其中一些表现出比喷他脒更大的协同活性。鲍曼不动杆菌、肺炎克雷伯菌、铜绿假单胞菌和大肠杆菌，包括耐多粘菌素和碳青霉烯的菌株。

  DOI：

  10.1021/acsinfecdis.1c00466

文献信息

• Amidine derivatives for treating amyloidosis
  申请人：Chalifour J. Robert

  公开号：US20070021483A1

  公开（公告）日：2007-01-25

  The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited:

  本发明涉及在治疗与淀粉样相关疾病中使用氨基脲类化合物。特别地，本发明涉及一种治疗或预防受试者淀粉样相关疾病的方法，包括向受试者施用治疗剂量的氨基脲类化合物。根据本发明使用的化合物包括以下化学式的化合物，当施用时，可减少或抑制淀粉样纤维形成、神经退行性或细胞毒性：
• Ashley et al., Journal of the Chemical Society, 1942, p. 103,107
  作者：Ashley et al.

  DOI：——

  日期：——
• Structure-Based Discovery of a Novel Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100B
  作者：Laura E. McKnight、E. Prabhu Raman、Padmavani Bezawada、Sucheta Kudrimoti、Paul T. Wilder、Kira G. Hartman、Raquel Godoy-Ruiz、Eric A. Toth、Andrew Coop、Alexander D. MacKerell、David J. Weber

  DOI：10.1021/ml300166s

  日期：2012.12.13

  Molecular dynamics simulations of the pentamidine-S100B complex, where two molecules of pentamidine bind per monomer of S100B, were performed in an effort to determine what properties would be desirable in a pentamidine-derived compound as an inhibitor for S100B. These simulations predicted that increasing the linker length of the compound would allow a single molecule to span both pentamidine binding sites on the protein. The resulting compound, SBi4211 (also known as heptamidine), was synthesized, and experiments to study its inhibition of S100B were performed. The 1.65 angstrom X-ray crystal structure was determined for Ca2+-S100B-heptamdine and gives high-resolution information about key contacts that facilitate the interaction between heptamidine and S100B. Additionally, NMR HSQC experiments with both compounds show that heptamidine interacts with the same region of SlOOB as pentamidine. Heptamidine is able to selectively kill melanoma cells with SlOOB over those without S100B, indicating that its binding to SlOOB has an inhibitory effect and that this compound may be useful in designing higher affinity SlOOB inhibitors as a treatment for melanoma and other S100B-related cancers.
• Structure–Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens
  作者：Charlotte M. J. Wesseling、Cornelis J. Slingerland、Shanice Veraar、Samantha Lok、Nathaniel I. Martin

  DOI：10.1021/acsinfecdis.1c00466

  日期：2021.12.10

  observed synergistic activity reported for pentamidine, while further assessing the capacity for structurally similar bis-amidines to also potentiate Gram-positive specific antibiotics against Gram-negative pathogens. Among the bis-amidines prepared, a number of them were found to exhibit synergistic activity greater than pentamidine. These synergists were shown to effectively potentiate the activity of

  喷他脒是一种 FDA 批准的抗寄生虫药，最近被鉴定为一种外膜破坏增效剂，可增强红霉素、利福平和新生霉素对革兰氏阴性菌的作用。同一项研究还描述了使用市售喷他脒类似物的初步构效关系。我们在这里报告了受喷他脒启发的更广泛的双脒组的设计、合成和评估。本研究既验证了先前观察到的喷他脒的协同活性，同时进一步评估了结构相似的双脒增强革兰氏阳性特异性抗生素对抗革兰氏阴性病原体的能力。在制备的双脒中，发现其中一些表现出比喷他脒更大的协同活性。鲍曼不动杆菌、肺炎克雷伯菌、铜绿假单胞菌和大肠杆菌，包括耐多粘菌素和碳青霉烯的菌株。
• Small Molecule Inhibitors of Ca²⁺-S100B Reveal Two Protein Conformations
  作者：Michael C. Cavalier、Mohd. Imran Ansari、Adam D. Pierce、Paul T. Wilder、Laura E. McKnight、E. Prabhu Raman、David B. Neau、Padmavani Bezawada、Milad J. Alasady、Thomas H. Charpentier、Kristen M. Varney、Eric A. Toth、Alexander D. MacKerell、Andrew Coop、David J. Weber

  DOI：10.1021/acs.jmedchem.5b01369

  日期：2016.1.28

  The drug pentamidine inhibits calcium-dependent complex formation with p53 ((Ca)S100Bp53) in malignant melanoma (MM) and restores p53 tumor suppressor activity in vivo. However, off-target effects associated with this drug were problematic in MM patients. Structure-activity relationship (SAR) studies were therefore completed here with 23 pentamidine analogues, and X-ray structures of (Ca)S100Binhibitor complexes revealed that the C-terminus of S100B adopts two different conformations, with location of Phe87 and Phe88 being the distinguishing feature and termed the FF-gate. For symmetric pentamidine analogues ((Ca)S100B5a, (Ca)S100B6b) a channel between sites 1 and 2 on S100B was occluded by residue Phe88, but for an asymmetric pentamidine analogue ((Ca)S100B17), this same channel was open. The (Ca)S100B17 structure illustrates, for the first time, a pentamidine analog capable of binding the open form of the FF-gate and provides a means to block all three hot spots on (Ca)S100B, which will impact next generation (Ca)S100Bp53 inhibitor design.